קוראלאן 7.5 מג ישראל - עברית - Ministry of Health

קוראלאן 7.5 מג

medison pharma ltd - ivabradine as hydrochloride - טבליות מצופות פילם - ivabradine as hydrochloride 7.5 mg - ivabradine - ivabradine - symptomatic treatment of chronic stable angina pectoris in patients with normal sinus rhythm, who have a contra-indication or intolerance for beta-blockers.

קוראלאן 5 מג ישראל - עברית - Ministry of Health

קוראלאן 5 מג

medison pharma ltd - ivabradine as hydrochloride - טבליות מצופות פילם - ivabradine as hydrochloride 5 mg - ivabradine - ivabradine - symptomatic treatment of chronic stable angina pectoris in patients with normal sinus rhythm, who have a contra-indication or intolerance for beta-blockers.

אלפו-קל XL ישראל - עברית - Ministry of Health

אלפו-קל xl

padagis israel agencies ltd, israel - alfuzosin hydrochloride - טבליות בשחרור ממושך - alfuzosin hydrochloride 10 mg - alfuzosin - alfuzosin - treatment of certain functional symptoms of benign prostatic hypertrophy, particularly if surgery has to be delayed for some reason.

רפמיון תמיסה ישראל - עברית - Ministry of Health

רפמיון תמיסה

pfizer pharmaceuticals israel ltd - sirolimus - תמיסה (פומי) - sirolimus 1 mg/ml - sirolimus - sirolimus - rapamune is indicated for the prophylaxis of organ rejection in adult patients at low to moderate immunological risk receiving a renal transplant. it is recommended that rapamune be used initially in combination with cyclosporine microemulsion and corticosteroids for 2 to 3 months. rapamune may be continued as maintenance therapy with corticosteroids only if cyclosporine can be progressively discontinued.

מיפלוניד אבקה לאינהלציה 200 מקגקפסולה ישראל - עברית - Ministry of Health

מיפלוניד אבקה לאינהלציה 200 מקגקפסולה

novartis israel ltd - budesonide - קפסולות - budesonide 200 mcg - budesonide - budesonide - maintenance treatment of bronchial asthma.

טייקרב ישראל - עברית - Ministry of Health

טייקרב

novartis israel ltd - lapatinib as ditosylate monohydrate - טבליות מצופות פילם - lapatinib as ditosylate monohydrate 250 mg - protein kinase inhibitors - tykerb is indicated for the treatment of adult patients with breast cancer, whose tumours overexpress her2 (erbb2);• in combination with capecitabine for patients with advanced or metastatic disease with progression following prior therapy, which must have included anthracyclines and taxanes and therapy with trastuzumab in the metastatic setting (see section 5.1).• tykerb is indicated in combination with letrozole for the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer that overexpresses the her2 receptor for whom hormonal therapy is indicated. tykerb in combination with an aromatase inhibitor has not been compared to a trastuzumab-containing chemotherapy regimen for the treatment of metastatic breast cancer.

סרדלגה ישראל - עברית - Ministry of Health

סרדלגה

sanofi israel ltd - eliglustat - קפסולה קשיחה - eliglustat 84.4 mg - eliglustat